SCHEMBL7064347

SCHEMBL7064347

COC(=O)C(=O)c1c[nH]c2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.48
CYP2C19 P33261 1/20 0.46
NR4A2 P43354 5/20 0.44
CREBBP Q92793 1/20 0.44
KDM4E B2RXH2 2/20 0.40
KDR P35968 2/20 0.40
HAT1 O14929 1/20 0.40
EP300 Q09472 1/20 0.40
ALOX5 P09917 1/20 0.39
FLT3 P36888 1/20 0.39
GSK3B P49841 1/20 0.39
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15389085 0.85 MAP2K1 (0.61) MAP2K1NR4A2CREBBPKDM4EMAPT
SCHEMBL31753964 0.85 MAP2K1 (0.61) MAP2K1NR4A2CREBBPKDM4EMAPT
SCHEMBL1993768 0.85 CYP2C19 (0.43) MAP2K1CYP2C19KDM4EKDRMAPT
SCHEMBL6432355 0.81 CYP2C19 (0.49) MAP2K1CYP2C19KDM4EHAT1EP300
SCHEMBL3889448 0.80 PARP1 (0.47) MAP2K1CYP2C19KDM4EHAT1EP300
Potassium Ion SCHEMBL7064340 0.80 CYP2C19 (0.46) MAP2K1CYP2C19KDM4EHAT1EP300
SCHEMBL12479995 0.80 PBRM1 (0.54) MAP2K1CYP2C19NR4A2CREBBPKDM4E
SCHEMBL29601281 0.80 PBRM1 (0.54) MAP2K1CYP2C19NR4A2CREBBPKDM4E
SCHEMBL2816680 0.78 TET2 (0.51) CYP2C19KDM4EHAT1EP300MAPT
SCHEMBL29600892 0.78 TET2 (0.51) CYP2C19KDM4EHAT1EP300MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030181463-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181463-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 MAP2K1 3885/4885CYP2C19 3101/4885NR4A2 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.